 |
 |
 |
 |
 |
 |
 |
 |
|
||||||||
|
SELECT PUBLICATIONS
Czuczman M et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005;23(19):4390-8. Abstract
Ganjoo K et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis. Leukemia and Lymphoma 2006;47(6):998-1005. Abstract
Gutierrez M et al. Dose-adjusted EPOCH chemotherapy (CT) and rituximab (EPOCHR): An effective regimen in poor prognosis aggressive B-cell non-Hodgkin’s lymphoma (NHL). Proc ASCO 2000; Abstract 95.
Hariharan H et al. Combining galiximab with the chemotherapeutic agents fludarabine or doxorubicin improves efficacy in animal models of lymphoma. Proc ASCO 2007; Abstract 3040.
Kahl B et al. A feasibility study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma. Proc ASCO 2007;Abstract 8062.
Kaminski MS et al. I131-tositumomab monotherapy as frontline treatment for follicular lymphoma: Updated results after a median follow-up of 8 years. Proc ASCO 2007; Abstract 8033.
Stopeck AT et al. Phase II trial of single agent bevacizumab (Avastin) in patients with relapsed, aggressive non-Hodgkin’s lymphoma (NHL): Southwest Oncology Group Study S0108. Proc ASCO 2005. Abstract 6592.
Wilson WH et al. Phase II study of dose-adjusted EPOCH-rituximab in untreated high risk large B-cell lymphomas. Proc ASCO 2001; Abstract 1158.
| Table of Contents | Top of Page |
